Note: The stock trades discussed in this article come from AI Finance Labs, an investment experiment that operates publicly viewable portfolios directed by models including Claude, ChatGPT, Grok and DeepSeek.
Anthropic’s Claude AI recently sold its positions in Ardelyx Inc. (NASDAQ: ARDX) and Aris Mining Corp. (NYSE: ARIS) and replaced them with Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) and BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX).
Syndax develops cancer treatments, and it was among our most promising cancer stocks to buy coverage earlier this year. BioCryst develops oral treatments for rare diseases. In this article, we will focus on BCRX.
Why Claude Bought BioCryst
Its main product is Orladeyo, a once-daily oral medicine used to prevent attacks of hereditary angioedema, a rare genetic disorder that causes potentially serious swelling.
BioCryst shares recently came under pressure after Pharvaris reported positive late-stage results for deucrictibant, another oral treatment for hereditary angioedema. The results raised concerns that the rival could eventually take market share from Orladeyo.
Claude says the selloff went too far. Pharvaris is not expected to launch the drug for preventive treatment until around 2028, giving BioCryst time to continue expanding Orladeyo sales.
The purchase also provides a hedge against Claude’s existing investment in Pharvaris, which represents about 7.6% of the portfolio. Positive news for Pharvaris could hurt BioCryst, while stronger-than-expected Orladeyo performance could support BioCryst and weigh on expectations for its rival.
According to Claude, investors should watch BioCryst’s early November earnings report for new-patient trends and management’s 2027 outlook. If new prescriptions weaken or the company forecasts flat to declining sales, Claude’s rebound thesis could quickly fall apart.
BioCryst Pharmaceuticals has a long growth runway in the hereditary angioedema market because Orladeyo, its oral pill, has patent protection until May 2040. The company has a second growth driver in navenibart, which it got by buying Astria Therapeutics. Patients would take navenibart every 3 to 6 months. Rival injections are given every 2 to 8 weeks, so navenibart’s schedule is much longer, and that could win over patients who want fewer shots. In an early trial, the drug cut attack rates by 93.4% in the first group and by 100% in the other two groups. Phase 3 results are due in the third quarter of 2027.
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.